Ann: Kazia Annual Report to shareholders, page-18

Go fish, this (yours) is the resolution I have come too as well - though I initially held the same view as KS... get the drug to market and extra 6 months at 1 billion a year says it all!

I noted that in the latest interview James spoke more about the PRV’s value than about the time saved pulling the drug through FDA quicker.

but getting to market quickly is critical for revenues

I note also that there is a fast track designation already applied and if DiPG has no current treatment if we show efficacy I’m sure it will be quick and a 100 million USD is 140 million AUD look at current burn rates with that runway in mind.

there’s also an argument to say that you could obtain a PRV on DiPG and use it on GBM... but I think they are looking at the $ on this one and Sanofi bought two of them $67 and 250 odd USD each in million.... James is from Sanofi I think it’s the $

either way they will make the safest and best choice To secure the companies overall program I have no doubt of that.